MSS

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Retrieved on: 
Monday, April 8, 2024
TME, FAP, Cell, Immunotherapy, Colorectal cancer, Mink, Patient, Tumor microenvironment, Cancer, PST, AACR, MSS, Neoplasm, Therapy, CRC, Liver, Liver disease, Vaccine

The data presented at AACR demonstrate MiNK-215's potential to effectively combat colorectal liver metastases, offering hope for patients who have exhausted conventional treatment options,” said Dr. Jennifer Buell, President and Chief Executive Officer at MiNK.

Key Points: 
  • The data presented at AACR demonstrate MiNK-215's potential to effectively combat colorectal liver metastases, offering hope for patients who have exhausted conventional treatment options,” said Dr. Jennifer Buell, President and Chief Executive Officer at MiNK.
  • This collaboration holds promise in bolstering the anti-tumor response, particularly in the formidable realm of microsatellite stable colorectal cancer."
  • Liver mets have limited the efficacy of immunotherapy in patients with mismatch repair proficient/microsatellite-stable (pMMR/MSS) colorectal cancer (CRC).
  • MiNK's innovative iNKT cell therapy, MiNK-215, has shown the ability to remodel the immunosuppressive tumor microenvironment within the liver.

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
FC, TME, Administration, Cell, Partnership, Patient, Gilead Sciences, Pharming, Research, Tumor microenvironment, G&A, Cancer, PacWest Bancorp, AACR, MSS, Investment, Therapy, CRC, Safety, Workforce, PD-1, Pharmaceutical industry

WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) --  Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Xilio today reaffirmed plans to:
    Select a recommended Phase 2 dose for XTX101 in combination with atezolizumab in the second quarter of 2024.
  • In March 2024, Xilio and Gilead Sciences, Inc. (Gilead) announced an exclusive license agreement for Xilio’s tumor-activated IL-12 program, including XTX301.
  • Xilio will also be eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales.
  • Net Loss: Net loss was $17.7 million for the quarter ended December 31, 2023, compared to $22.5 million for the quarter ended December 31, 2022.

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite St

Retrieved on: 
Monday, April 1, 2024
Lung cancer, Survival, Immunotherapy, Disease, Colorectal cancer, Progression-free survival, Medicine, Patient, Common, DNA, Aes, Cancer, Death, Doctor of Philosophy, Gritstone bio, MD, Kinetics, Induction chemotherapy, MSS, Circulating tumor DNA, VAF, Melanoma, PFS, Vaccine, Data, UCLA, Liver disease, Neoplasm, Pharmaceutical industry

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC). The randomized, controlled, open-label study is designed to quantify the clinical benefit of maintenance therapy with GRANITE (GRT-C901/GRT-R902) in combination with immune checkpoint blockade in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone. Overall progression free survival (PFS) data show an early trend in benefit for GRANITE patients (HR=0.82, [95% CI, 0.34-1.67]; 62% censored) and extended PFS benefit in high-risk patients (HR=0.52 [95% CI, 0.15-1.38]; 44% censored), in whom progression occurs faster. Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis (molecular response as defined per protocol) did not demonstrate a difference between study arms. Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).

Key Points: 
  • Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).
  • “Today's preliminary Phase 2 results are highly encouraging and represent the first randomized trial evidence, albeit early, that a personalized neoantigen-directed vaccine can potentially drive efficacy in a metastatic ‘cold’ tumor.
  • Fortunately, long-term analysis demonstrates the expected correlation of ctDNA with clinical benefit and favors GRANITE patients.
  • This analysis was performed on 44 patients who received study treatment (control and GRANITE arms) and have available baseline ctDNA data.

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Head, Immunotherapy, HNSCC, Patient, Roche, Lead, Immunoglobulin G, Neoplasm, CRC, Audit committee, PD-1, Observation, Bioinformatics, Colorectal cancer, SAN, Information technology, Pembrolizumab, PRS, Safety, PD-L1, Compensated emancipation, Annual report, Apoptosis, Cervical cancer, Part, Merck, Senior, Bevacizumab, MSS, GAAP, ASCO, PFS, MTD, Liver disease, HCC, Therapeutic index, Endometrial cancer, Progression-free survival, ADS, Net, Regulatory T cell, Research and development, Liver, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full year 2023 and provided corporate updates.

Key Points: 
  • Both confirmed PRs are sustained after more than one year with repeat dosing while maintaining robust safety profiles.
  • Observation of these clinical activities triggered further expansion into the second stage of the Simon’s 2-stage design for this dose level.
  • Net loss attributable to Adagene Inc.’s shareholders was US$18.9 million for the year ended December 31, 2023, compared to US$80.0 million in 2022.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Welcome to TeKnowledge: Accelerating Progress. Securing Futures.

Retrieved on: 
Tuesday, April 9, 2024
Consulting, Data Management, Technology, Professional Services, Security, Other Technology, Telecommunications, Software, Networks, Internet, Hardware, Transfer, Microsoft, Organization, Growth, Roche, CISO, Ria Money Transfer, Aileen, MSS, Fortune 500, Managed security service, Multimedia, Government, HP, Management

Under the guidance of Aileen Allkins, President and CEO, TeKnowledge is pioneering new frontiers in digital services.

Key Points: 
  • Under the guidance of Aileen Allkins, President and CEO, TeKnowledge is pioneering new frontiers in digital services.
  • Their collective skills in global operations, cybersecurity, digital transformation, and customer experience, honed over decades, are crucial in navigating the digital landscape's complexities.
  • Our approach integrates these services seamlessly, maximizing efficiency, simplifying processes, and accelerating the achievement of strategic imperatives with unparalleled precision and efficacy."
  • Dynamic Cybersecurity Services: With an all-encompassing suite of advisory and Managed Security Services (MSS) offerings, TeKnowledge (f.k.a.

AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

Retrieved on: 
Tuesday, April 9, 2024
Research, Clinical Trials, Biometrics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Cancer, Doctor, MSI-H, Metastasis, Communication, Immunotherapy, Colorectal cancer, Patient, MSI, STC, Team, Doctor of Philosophy, Master of Science, MSS, Neoplasm, Vaccine

This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.

Key Points: 
  • This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.
  • Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.
  • STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors.
  • Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured.

Agenus Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Oncology, OS, BOT, Colitis, Inc., Colorectal cancer, PD, RECIST, IST, Partnership, RAS, Patient, MSI, FOLFIRINOX, BMS, Melanoma, MSS, BAL, Cancer, CRC, NLM, TIGIT, Liver disease, Pharmaceutical industry

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Key Points: 
  • Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.
  • “In 2023, Agenus made significant advances across our BOT/BAL development program.
  • $25 million milestone payment from BMS triggered by the commencement of a Phase 2 study with BMS-986442 in December 2023.
  • For the fourth quarter ended December 31, 2023, we recognized revenue of $84 million and incurred a net loss of $49 million or $0.13 per share.

Singtel Awarded Frost & Sullivan's 2023 Singapore Company of the Year Award for Its Strong Industry Leadership Position in Cybersecurity Services

Retrieved on: 
Saturday, March 30, 2024
The Security Institute, SOC, Organization, CSI, Frost, PSS, Intelligence, SAN, Glass, Queen bee, Architecture, MSS, PUA, Telecommunications, SME, Risk management

SAN ANTONIO, March 29, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the cybersecurity services industry and, based on its findings, recognizes Singtel with the 2023 Singapore Company of the Year Award. Singtel is Singapore's major telecommunications provider that delivers comprehensive network-centric security solutions to safeguard businesses against unauthorized access, data breaches, and cyber threats through managed security services (MSS), professional security services (PSS), and the Singtel Cyber Security Institute (CSI), spanning all dimensions of cybersecurity to secure businesses' most critical digital assets.

Key Points: 
  • Singtel is reputable in the cybersecurity services industry, driven by its robust investment in innovation, unwavering commitment to expanding cybersecurity service offerings, comprehensive security solutions, and premium support.
  • SAN ANTONIO, March 29, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the cybersecurity services industry and, based on its findings, recognizes Singtel with the 2023 Singapore Company of the Year Award.
  • As a result, with its ever-growing customer base and strong leadership in the Singapore cybersecurity services industry, Singtel has successfully proved its market expertise and innovative character, compared to its closest competitors.
  • Industry analysts compare industry participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

Singtel Awarded Frost & Sullivan's 2023 Singapore Company of the Year Award for Its Strong Industry Leadership Position in Cybersecurity Services

Retrieved on: 
Saturday, March 30, 2024
The Security Institute, SOC, Organization, CSI, Frost, PSS, Intelligence, SAN, Glass, Queen bee, Architecture, MSS, PUA, Telecommunications, SME, Risk management

SAN ANTONIO, March 30, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the cybersecurity services industry and, based on its findings, recognizes Singtel with the 2023 Singapore Company of the Year Award. Singtel is Singapore's major telecommunications provider that delivers comprehensive network-centric security solutions to safeguard businesses against unauthorized access, data breaches, and cyber threats through managed security services (MSS), professional security services (PSS), and the Singtel Cyber Security Institute (CSI), spanning all dimensions of cybersecurity to secure businesses' most critical digital assets.

Key Points: 
  • Singtel is reputable in the cybersecurity services industry, driven by its robust investment in innovation, unwavering commitment to expanding cybersecurity service offerings, comprehensive security solutions, and premium support.
  • SAN ANTONIO, March 30, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the cybersecurity services industry and, based on its findings, recognizes Singtel with the 2023 Singapore Company of the Year Award.
  • As a result, with its ever-growing customer base and strong leadership in the Singapore cybersecurity services industry, Singtel has successfully proved its market expertise and innovative character, compared to its closest competitors.
  • Industry analysts compare industry participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, March 28, 2024
Abstract, NCI, FOLFIRI, Prostate cancer, Immunotherapy, Adenocarcinoma, Colorectal cancer, PDLIM2, Physician, Patient, Lung, Biomarker, MSI, Breast, Cancer, AI, Doctor of Philosophy, Special session, MD, Lung cancer, Medicine, MBA, FOLFOX, AACR, PIM, MSS, Booth, POA, MRD, Future, Prognosis, SSP, ANTXR1, Vaccine

IRVING, Texas, March 28, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 10 studies across eight tumor types at the 2024 American Association for Cancer Research (AACR) Annual Meeting on April 5-10, 2024, in San Diego, CA, at Booth Number 1105. Caris President, David Spetzler, MS, PhD, MBA, will lead an AACR Scientist ↔ Survivor Program® Special Session titled, "Very Early Cancer Detection Assays: The Future or Fantasy," on Tuesday, April 9, from 1:00 – 1:45 PM.

Key Points: 
  • Tissue-specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers.
  • (Poster Number: 7037/4)
    Poster and abstract summaries highlighting the Caris research presented at AACR 2024 will be available onsite at Caris' Booth (# 1105).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.
  • POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.